Hello, everyone, and how are you today? We are doing just fine, thank you, since a warm and shiny sun is enveloping the quiet Pharmalot campus. Our short person has left for the local schoolhouse and our mascots are comfortably snoozing in their respective corners. As for us, we are, as usual, keeping busy by looking for interesting items and having interesting conversations. Have something to say? Drop us a line. Meanwhile, here are some tidbits. Hope you conquer the world today …

Spark Therapeutics (ONCE), whose breakthrough gene therapy to treat a rare form of blindness was approved by U.S. regulators in December, has licensed rights to the drug outside the U.S. to Novartis (NVS) for up to $170 million, Reuters notes. Spark will keep U.S. rights to Luxturna, which is the first approved gene therapy for an inherited disease. The company plans to launch the one-time treatment in March, charging an unprecedented $850,000.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy